CPC A61K 47/645 (2017.08) [A61K 9/0021 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 47/32 (2013.01); A61K 47/56 (2017.08); A61K 47/61 (2017.08); A61K 47/6903 (2017.08); A61M 37/0015 (2013.01); A61P 3/10 (2018.01); B29C 39/026 (2013.01); B29C 39/123 (2013.01); C12N 15/115 (2013.01); A61M 2037/0023 (2013.01); A61M 2037/0053 (2013.01); A61M 2037/0061 (2013.01); B29K 2105/0035 (2013.01); B29K 2995/006 (2013.01); B29K 2995/0092 (2013.01); B29L 2031/756 (2013.01); B29L 2031/7544 (2013.01); C12N 2310/16 (2013.01)] | 29 Claims |
1. A composition comprising:
(a) a polymer-insulin conjugate comprising a polymer covalently conjugated to insulin or to a bioactive derivative thereof, wherein said polymer is a hydrophilic polymer selected from the group consisting of a polysaccharide, polyglutamic acid, and a hydrophilic synthetic block copolymer, and wherein the insulin or bioactive derivative thereof is selected from the group consisting of a human insulin, a recombinant human insulin, an insulin from a non-human animal, a fast-acting insulin, an intermediate-acting insulin, a long-acting insulin, and combinations thereof; and
(b) an insulin aptamer-glucagon conjugate comprising an insulin aptamer covalently conjugated to glucagon or to a bioactive derivative thereof, wherein said insulin aptamer is an oligonucleotide, and wherein said bioactive derivative retains at least some of the biological activity of endogenous glucagon;
wherein the insulin aptamer can selectively bind to the insulin or bioactive derivative thereof, thereby forming a non-covalent conjugate between (a) and (b).
|